Traws Pharma (TRAW) director granted 11,530 options at $3.01

Traws Pharma (TRAW) disclosed a Form 4 showing a director received a stock option grant.

Accepted by SEC EDGAR 10/15/2025 - 12:00 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Traws Pharma (TRAW) disclosed a Form 4 showing a director received a stock option grant. The award covers 11,530 options with an exercise price of $3.01 per share, granted on October 12, 2025.

The options vest 100% on the first anniversary of the grant date and become exercisable on October 12, 2026, with an expiration on October 12, 2035. Following the transaction, the reporting person held 11,530 derivative securities, reported as Direct (D) ownership.

Insider Trade Summary

Grant/Award: 11,530 shares

Grant/Award 1 txn

Insider STOVER JACK E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to purchase)	11,530	$0.00	$0.00

Holdings After Transaction: Stock Option (right to purchase) — 11,530 contracts (Direct)

Holdings Before and After: Stock Option (right to purchase), 0 to 11,530 contracts (Direct)

Footnotes (1)

1. F1. The options vest 100% on the first anniversary of the grant date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Traws Pharma (TRAW) report in this Form 4?

A director was granted 11,530 stock options at an $3.01 exercise price on October 12, 2025.

When do the TRAW options vest and become exercisable?

They vest 100% on the first anniversary of the grant and are exercisable on October 12, 2026.

What is the expiration date of the Traws Pharma director options?

The options expire on October 12, 2035.

How many derivative securities does the reporting person hold after the transaction?

The reporting person holds 11,530 derivative securities following the grant.

What is the ownership form reported for these options?

The options are reported as Direct (D) ownership.

What role does the reporting person have at Traws Pharma (TRAW)?

The reporting person is a Director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

STOVER JACK E

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC

12 PENNS TRAIL

(Street)

NEWTOWN PA 18940

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to purchase)	$3.01	10/12/2025		A		11,530		10/12/2026(1)	10/12/2035	Common Stock	11,530	$0	11,530	D

Explanation of Responses:

1. The options vest 100% on the first anniversary of the grant date.

	/s/ Jack E. Stover	10/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.